Cancer is the second leading cause of death worldwide, after cardiovascular disease. Its development and progression are often driven by mutations or overactivation of cell signaling pathways, which not only promote tumor growth but also contribute to resistance to therapy. One key pathway implicated in roughly one-third of all solid tumors is the RAS/MAPK pathway, which plays a critical role in cancers such as colorectal cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma.
The stock we are bringing to your attention today is that of Erasca Inc. (ERAS), a clinical-stage precision oncology company focused on therapies for RAS- and MAPK pathway-driven cancers. Its lead drug candidates include ERAS-0015, ERAS-4001, and Naporafenib.
For comments and feedback: editorial@rttnews.com